COMUNICATO STAMPA

SVAS BIOSANA S.p.A.

- ***ADMITTED TO NEGOTIATIONS ON THE EURONEXT GROWTH MILAN***
- ***PLACEMENT OF ORDINARY SHARES SUCCESSFULLY CLOSED, WITH A DEMAND MORE THAN 3 TIMES HIGHER THAN OFFERING***
- ***TOTAL PLACEMENT VALUE EQUAL TO AROUND EUR 23 MILLION AT AN OFFER PRICE OF EUR 12,50 PER SHARE, CORRESPONDING TO A POST-CAPITAL INCREASE MARKET CAP OF EUR 70 MILLION***
- ***FREE FLOAT ON THE MARKET EQUAL TO 28,6% (32,9% POST GREENSHOE)***
- ***FIRST TRADING DAY OF SHARES AND WARRANTS SCHEDULED FOR 9TH DECEMBER 2021***

Somma Vesuviana (NA) 7th December 2021 – Svas Biosana S.p.A., (the "**Company**" or "**SVAS**) leading operator in the healthcare sector, active in the production and distribution of medical devices for public and private healthcare facilities, announces that, today, Borsa Italiana S.p.A. **admitted to listing Svas Biosana ordinary shares and warrants** ("**Warrant Svas Biosana 2021-2024**") on the **Euronext Growth Milan** - multilateral trading system organized and managed by Borsa Italiana dedicated to small and medium-sized enterprises with high growth potential, after successfully completing the placement of its ordinary shares with a total raising of approximately Eur 23 million (including the over allotment option of approximately Euro 3 million) with a demand more than 3 times higher than offering.

The first trading day is scheduled for **Thursday, 9th December 2021**.

"*We are very satisfied*" commented **Umberto Perillo**, Chief Executive Officer of **SVAS Biosana S.p.A.** "*of the admission to negotiations and of the interest that we found among the investors. We thank them for their trust, even more so considering the complex economical context that still persists, thus rewarding our entrepreneurial project. The raised financial resources will allow us to support our development programs with greater tenacity, further strengthen our market position at national and international level and to also grow by external lines. Today SVAS has greater skills, a stronger team, a recognized market positioning and greater financial resources available to successfully implement its growth strategy. We are pleased to be able to share our development projects and future results with our new Shareholders and with the market*".

Admission to negotiations took place following the placement - aimed at Italian and foreign institutional and professional investors - which generated a demand 3 times higher than the offered quantity. The placement involved a total of 1,600,000 ordinary shares deriving from a specific capital increase and no. 240,000 shares intended for the exercise of the over allotment option granted by the shareholder Agrinvest S.r.l. to Banca Profilo and to illimity Bank as Joint-Global Coordinators (corresponding to 15% of the shares subject of the offer).

As part of the placement, the total value of the resources raised was equal to Eur 23 million, with a price for each share determined at EUR **12.50** per share with a total market capitalization at the start of negotiations of approximately **EUR 70 million** and a free float of 28.6% pre-greenshoe (free float of 32.9% in the event of full exercise of the greenshoe option). As a result of the placement, the Company's share capital is composed by no. 5,600,000 shares.

The operation also includes the issue of "**Warrant Svas Biosana 2021-2024**", to be assigned free of charge in the ratio of no. 1 warrant for every 2 ordinary shares to all those who have subscribed the ordinary shares during the placement. The settlement of the warrants considers a strike price increased by 15% with respect to the placement price in the first period of exercise; the increase will be 30% in the second operating period and 60% in the third operating period. The share swap ratio is established in 1 Conversion Share for each Warrant exercised.

The Company has been assigned the following identification codes:
- ISIN Ordinary Shares: IT0005469264
- ISIN Warrant SVAS BIOSANA 2021-2024: IT0005469157

In the listing process, Svas Biosana S.p.A. is assisted by Banca Profilo (Euronext Growth Advisor and Joint-Global Coordinator of the operation), illimity Bank (Joint Global Coordinator of the operation), Banca Finint (Financial Advisor of the Issuer), Grimaldi Studio Legale (Legal Advisor of the Issuer and of the Joint Global Coordinators), PwC Italia (Auditing Firm), A2B Group (Consultant for non-accounting data) and Polytems HIR (Communication Advisor).

The Admission Document and the Regulations of the "Warrant Svas Biosana 2021-2024" are available at the Company's registered office and on the website www.svas.it

* * * * * * * *

Contacts:

SVAS Biosana S.p.A.
Andrea Efficace
CFO Group & Investor Relations Manager
+39 081.8995411
a.efficace@svas.it

Euronext Growth Advisor
Banca Profilo
Milano, Via Cerva 128
+39 02.584081
alessio muretti@bancaprofilo.it

Investor Relations Advisor
POLYTEMS HIR
Bianca FERSINI MASTELLONI - Silvia MARONGIU
06.69923324-066797849
s.marongiu@polytemshir.it

Media Relations Advisor
POLYTEMS HIR
Paolo SANTAGOSTINO
+393493856585
p.santagostino@polytemshir.it

Svas Biosana produces and distributes medical devices in Italy and abroad. Founded in 1972 in Somma Vesuviana (NA) by the Perillo family, today SVAS is an international company with a product portfolio of approximately 16,000 articles from own and third party brands, 367 employees, a department dedicated to Research and Development, 3 production plants in Italy and subsidiaries in Slovenia, Croatia, Serbia and Bosnia and Herzegovina.

SVAS BIOSANA S.p.A.
Registro Imprese di
Napoli n.4543/85
n. R.E.A. 393065
C.F. 04720630633
P. I.V.A. 01354901215

Sede Legale
Via M. Perillo, 34
80047
San Giuseppe Vesuviano (NA)
Italy

Corrispondenza
Casella Postale n.91
80049
Somma Vesuviana (NA)
Italy

Direzione ed Uffici
Via Trentola, 7
80049
Somma Vesuviana (NA)
Italy

Contatti
Tel. +390818995411
Fax +390818993922
www.svas.it
svasbiosana@legalmail.it